Dendritic cells and cancer: Progress toward a new cellular therapy

Journal of Hematotherapy and Stem Cell Research

Volumn 6, Issue 6, 1997, Pages 523-533

  Troy, A J ^a   Hart, D N J ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS;

EID: 0031415650     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271, 1991.
2. Austyn, J.M. New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med. 183:1287, 1996.
3. Hart, D.N.J. Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 90:3245, 1997.
4. Boon, T., Cerottini, J.C., Eynde, B., et al. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337, 1994.
5. Hsu, F.J., Benike, C., Fagnoni, F., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52, 1996.
6. Murphy, G., Tjoa, B., Ragde, H., et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29:371, 1996.
7. Nestle, F.O., Gilliet, M., Alljagic, S., et al. Vaccination of melanoma patients with peptide-pulsed dendritic cells. Melanoma Res. 7:S14, 1997.
8. Metlay, J.P., Witmer-Pack, M.D., Agger, R., et al. The distinct leukocyte integrins of mouse spleen DC as identified with new hamster mAb. J. Exp. Med. 171:1753, 1990.
9. Jiang, W., Swiggard, W.J., Heufler, C., et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375:151, 1995.
10. Zhou, L.J. & Tedder, T.F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154:3821, 1995.
11. Hock, B.D., Starling, G.C., Daniel, P.B., et al. Characterisation of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology 83:573, 1994.
12. Hock, B.D., Fearnley, D., Sorg, R.V., et al. Characterisation of CMRF-56, a selective marker for activated human dendritic cell populations. In preparation.
13. Kato, M., Neil, T., Clark, G., et al. The molecular cloning of human DEC-205, putative antigen-uptake receptor on DC. Immunogenetics 1998. In press.
14. Hart, D.N.J. & McKenzie, J.L. Interstitial dendritic cells. Int. Rev. Immunol. 6:127, 1990.
15. Roake, J.A., Rao, A.S., Morris, P.J., et al. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide tumor necrosis factor and interleukin 1. J. Exp. Med. 181:2237, 1995.
16. Fearnley, D.B., McLellan, A.D., Mannering, S.I., et al. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: Implications for studies on antigen presenting cell function and immunotherapy. Blood 89:3708, 1997.
17. Ardavin, C. & Shortman, K. Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature 362:761, 1993.
18. Suss, G. & Shortman, K. A subclass of dendritic cells kills CD4 T cells via Fas/fas-ligand-induced apoptosis. J. Exp. Med. 183:1789, 1996.
19. Kronin, V., Winkel, K., Suss, G., et al. A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production. J. Immunol. 157:3819, 1996.
20. Galy, A., Travis, M., Cen, D., et al. Human T, B, natural killer and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 3:459, 1995.
21. Williams, L.A., Egner, W. & Hart, D.N.J. Isolation and function of human dendritic cells. Int. Rev. Cytol. 153:41, 1994.
22. Young, J.W., Szabolcs, P. & Moore, M.A.S. Identification of dendritic cell colony-forming units among normal human CD344+ bone marrow progenitors that are expanded by c-kit ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor-α. J. Exp. Med. 182:1120, 1995.
23. Szabolcs, P., Moore, M.A.S. & Young, J.W. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J. Immunol. 154:5851, 1995.
24. Caux, C., Dezutter-Dambuyant, C., Schmitt, D., et al. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360:258, 1992.
25. Bernhard, H., Disis, M.L., Heimfeld, S., et al. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells in the bone marrow and peripheral blood. Cancer Res. 55:1099, 1995.
26. Mackensen, A., Herbst, B., Kohlter, G., et al. Delineation of the dendritic cell lineage by generating large numbers of birbeck granule-positive Langerhans cells from human peripheral blood progenitor cells in vitro. Blood 86:2699, 1995.
27. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-α. J. Exp. Med. 179:1109, 1994.
28. Lanzavecchia, A. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 8:348, 1996.
29. Watts, C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 15:821, 1997.
30. Kleijmeer, M.J., Ossevoort, M.A., van Veen, C.J.H., et al. MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells. J. Immunol. 154:5715, 1995.
31. Nijman, H.W., Kleijmeer, M.J., Ossevoort, M.A., et al. Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. J. Exp. Med. 182:163, 1995.
32. Norbury, C.C., Chambers, B.J., Prescott, A.R., et al. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur. J. Immunol. 27:280, 1997.
33. Lechler, R., Aichinger, G. & Lightstone, L. The endogenous pathway of MHC class II antigen presentation. Immunol. Rev. 151:51, 1996.
34. Guinan, E.G., Gribben, J.G., Boussiotis, V.A., et al. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261, 1994.
35. Schwartz, R.H. Models of T cell anergy: Is there a common molecular mechanism? J. Exp. Med. 184:1, 1996.
36. Gribben, J.G., Freeman, C.J., Boussiotis, V.A., et al. CTLA-4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. USA 92:811, 1995.
37. Gribben, J.G., Guinan, E.C., Boussiotis, V.A., et al. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool. Blood 87:4887, 1996.
38. McLellan, A.D., Sorg, R.V., Williams, L.A., et al. Human dendritic cells activate T lymphocytes via a CD40:CD40 ligand-dependent pathway. Eur. J. Immunol. 26:1204, 1996.
39. Kuchroo, V.K., Das, M.P., Brown, J.A., et al. B7.1 and B7.2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 80:707, 1995.
40. Heufler, C., Koch, R, Stanzl, U., et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur. J. Immunol. 26:659, 1996.
41. Mehrotra, P.T., Grant, A.J. & Siegel, J.P. Synergistic effects of IL-7 and IL-12 on human T cell activation. J. Immunol. 154:5093, 1995.
42. Ambe, K., Mori, M. & Enjoji, M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 63:496, 1989.
43. Furukawa, T., Watanabe, S., Kodama, T., et al. T-zone histiocytes in adenocarcinoma of the lung in relation to postoperative prognosis. Cancer 56:2651, 1985.
44. Tsujitani, S., Kakeji, Y., Watanabe, A., et al. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 66:2012, 1990.
45. Nomori, H., Watanabe, S., Nakajima, T., et al. Histiocytes in nasopharyngeal carcinoma in relation to prognosis. Cancer 57:100, 1986.
46. Imai, Y. & Yamakawa, M. Dendritic cells in esophageal cancer and lymph node tissues. In Vivo 7:239, 1993.
47. Kahn, H.J., Marks, A., Thom, H., et al. Role of antibody to S100 protein in diagnostic pathology. Am. J. Clin. Pathol. 79:341, 1983.
48. Fox, S.B., Jones, M., Dunnill, M.S., et al. Langerhans cells in human lung tumors: Immunohistological study. Histopathology 14:269, 1989.
49. Ioachim-Velogianni, E., Stavropoulos, N.B., Kitsiou, E., et al. Distribution of CD1A-positive Langerhans cells and lymphocyte subsets in transitional cell carcinoma of the urinary bladder. An immunohistological study on frozen sections. J. Pathol. 177:401, 1995.
50. Papadimitriou, C.S., Datseris, G., Costopoulos, J.S., et al. Langerhans cells and lymphocyte subsets in human gastrointestinal carcinomas. An immunohistological study on frozen sections. Pathol. Res. Pract. 188:989, 1992.
51. Chaux, P., Hammann, A., Martin, F., et al. Surface phenotype and functions of tumor-infiltrating dendritic cells: CD8 expression by a cell subpopulation. Eur. J. Immunol. 23:2517, 1993.
52. Troy, A.J., Summers, K.L., Davidson, P.J.T., et al. The dendritic cell infiltrate in human renal cell carcinoma: A probable mechanism for tumor escape from human surveillance. 1997. Submitted.
53. Gabrilovich, D.I., Chen, H.L., Girgis, K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1096, 1996.
54. Sato, T., McCue, P., Masuoka, K., et al. Interleukin 10 production by human melanoma. Clin. Cancer Res. 2:1383, 1996.
55. Willems, F., Marchant, A., Delville, J., et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol. 24:1007, 1994.
56. Groux, H., Bigler M., de Vries, J.E., et al. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J. Exp. Med. 184:19, 1996.
57. Lipscomb, M.F., Pollard, A.M. & Yates, J.L. A role for TGF-beta in the suppression by murine bronchoalveolar cells of lung dendritic cell initiated immune responses. Reg. Immunol. 5:151, 1993.
58. Summers, K.L., O'Donnell, J.L., Highton, J., et al. Rheumatoid synovial fluid TGF-β inhibits dendritic cell-T lymphocyte interactions. 1997. Submitted.
59. Gabrilovich, D.I., Nadaf, S., Corak, J., et al. Dendritic cells in antitumor immune responses. Cell. Immunol. 170:111, 1996.
60. Gabrilovich, D.I., Corak, J., Ciernik, I.F., et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 3:483, 1997.
61. Radmayr, C., Bock, G., Hobisch, A., et al. Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients. Int. J. Cancer 63:627, 1995.
62. Tjoa, B., Erickson, S., Barren, R., et al. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 27:63, 1995.
63. Lynch, D.H., Andreasen, A., Maraskovsky, E., et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3:625, 1997.
64. + T lymphocytes: Optimal presentation by blood dendritic cells. Blood 90:290, 1997.
65. Rabbitts, T.H. Chromosomal translocations in human cancer. Nature 372:143, 1994.
66. Gambacorti-Passerini, C., Bertazolli, C., Dermime, S., et al. Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers. Clin. Cancer Res. 3:675, 1997.
67. Gedde-Dahl, T., Fossum, B., Eriksen, J.A., et al. T cell clones specific for p21 ras-derived peptides: Characterization of their fine specificity and HLA restriction. Eur. J. Immunol. 23:754, 1993.
68. Houbiers, J.G.A., Nijman, H.W., van der Burg, S.H., et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23:2072, 1993.
69. van der Bruggen, P., Traversari, C., Chomez, P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643, 1991.
70. Apostolopoulos, V. & McKenzie, I.F.C. Cellular mucins: Targets for immunotherapy. Crit. Rev. Immunol. 14:293, 1994.
71. Kraus, S., Fischer, C., Nachtmann, et al. Expression of MUC-1 and the new trefoil peptide PS2 in human kidney and renal cell carcinoma. J. Urol. 157:108S, 1997.
72. Slovin, S.F., Livingstone, P., Keeperman, K., et al. Targeted therapy in prostate cancer: Vaccination with a glycoprotein, MUC-1-KLH-QS21 peptide conjugate. J. Urol 157:1605, 1997.
73. Barratt-Boyes, S.M. Making the most of mucin: A novel target for tumor immunotherapy. Cancer Immunol. Immunother. 43:142, 1996.
74. Brandle, D., Brasseur, F., Weynants, P., et al. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183:2501, 1996.
75. Gaugler, B., Brouwenstijn, N., Vantomme, V., et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 44:323, 1996.
76. Bernhard, H., Karbach, J., Woldfel, T., et al. Cellular immune response to human renal-cell carcinomas: Definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Int. J. Cancer 59:837, 1994.
77. Kwak, L.W., Campbell, M.J., Czerwinski, D.K., et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327:1236, 1992.
78. Nelson, E.L., Li, X., Hsu, F.J., et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88:580, 1996.
79. Kwak, L.W., Taub, D.D., Duffey, D.L., et al. Transfer of myeloma idiotype-specific immunity from an acutively immunised marrow donor. Lancet 345:1016, 1995.
80. Correale, P., Walmsley, K., Nieroda, C., et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. 89:293, 1997.
81. Tjoa, B., Boynton, A., Kenny, G., et al. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 28:65, 1996.
82. Mitropoulos, D., Kooi, S., Rodriguez-Villanueva, J., et al. Characterization of fresh (uncultured) tumor-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. Clin. Exp. Immunol. 97:321, 1994.
83. Kim, T., von Eschenbach, A.C., Filaccio, M.D., et al. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma. Cancer Res. 50:5263, 1990.
84. Goedegebuure, P.S., Douville, L.M., Li, H., et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. J. Clin. Oncol. 13:1939, 1995.
85. Belldegrun, A., Pierce, W., Kaboo, R., et al. Interferon-α primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-α as therapy for metastatic renal cell carcinoma. J. Urol. 150:1384, 1993.
86. Iezzi, G., Pia Protti, M., Rugarli, C., et al. B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Cancer Res. 56:11, 1996.
87. Perry, A.R. & Mackinnon, S. Adoptive immunotherapy post bone marrow transplantation. Blood Rev. 10:237, 1996.
88. Shurin, M.R. Dendritic cells presenting tumor antigen. Cancer Immunol. Immunother. 43:158, 1996.
89. Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation and T helper cell I-associated cytokines. J. Exp. Med. 183:87, 1996.
90. Barratt-Boyes, S.M., Watkins, S.C. & Finn, O.J. In vivo migration of dendritic cells differentiated in vitro. J. Immunol. 158:4543, 1997.
91. Condon, C., Watkins, S.C., Celluzzi, C.M., et al. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1122, 1996.
92. Gong, J., Chen, D., Kashiwaba, M., et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:558, 1997.
93. Falk, K., Rotzschke, O., Stevanovic, S., et al. Pool sequencing of natural HLA-DR, DQ and DP ligands reveals detailed peptide motifs, constraints of processing and general rules. Immunogenetics 39:230, 1994.
94. Knight, S.C., Hunt, R., Dore, C., et al. Influence of dendritic cells in tumor growth. Proc. Natl. Acad. Sci. USA 82:4495, 1985.
95. Grabbe, S., Bruvers, S., Gallo, R.L., et al. Tumor antigen presentation by murine epidermal cells. J. Immunol. 146:3656, 1991.
96. Flamand, V., Sornasse, T., Thielemans, K., et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24:605, 1994.
97. Shimizu, J., Zou, J., Ikegame, K., et al. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts. J. Immunol. 146:1708, 1991.
98. Cohen, P.J., Cohen, P.A., Rosenberg, S.A., et al. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur. J. Immunol. 24:315, 1994.
99. Young, J.W. & Inaba, K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183:7, 1996.
100. Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., et al. Peptide-pulsed dendritic cells induce antigen-specific, CLT-mediated protected tumor immunity. J. Exp. Med. 183:283, 1996.
101. Mayordomo, J.I., Zorina, T., Storkus, W.J., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1:1297, 1995.
102. Golumbek, P., Levitsky, H., Jaffee, L., et al. The antitumor immune response as a problem of self-nonself discrimination: Implications for immunotherapy. Immunol. Rev. 12:183, 1993.
103. van Elsas, A., van der Burg, S.H., van der Minne, C., et al. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the MelanA/MART-1 self-antigen. Eur. J. Immunol. 26:1683, 1996.
104. Bakker, A.B.H., Marland, G., de Boer, A.J., et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55:5330, 1995.
105. Reeves, M.E., Royal, R.E., Lam, J.S., et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 56:5672, 1996.
106. Henderson, R.A., Nimgaonkar, M.T., Watkins, S.C., et al. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res. 56:3763, 1996.
107. Karanikas, V., Hwang, L., Pearson, J., et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 1997. In press.
108. Zeid, N.A. & Muller, H.K. S100-positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 25:338, 1993.
109. Ohmori, T., Okada, K., Arita, N., et al. Characteristics of MHC antigen expression and tumor-infiltrating mononuclear cells in renal cell adenomas and carcinomas. Histol. Histopathol. 10:789, 1995.
110. Bigotti, G., Coli, A. & Castagnola, D. Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade. Prostate 19:73, 1991.
111. Inoue, K., Furihata, M., Ohtsuki, Y., et al. Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumor progression and prognosis. Pathol. Anat. Histopathol. 422:351, 1993.
112. Stene, M.A., Babajanians, M., Bhuta, S., et al. Quantitative alterations in cutaneous Langerhans cells during evolution of malignant melanoma of the skin. J. Invest. Dermatol. 91:125, 1988.
113. Paglia, P., Chiodoni, C., Rodolfo, M., et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317, 1996.
114. Porgador, A., Snyder, D. & Gilboa, E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918, 1996.